

Klaus Langer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2492312/publications.pdf>

Version: 2024-02-01

105
papers

7,123
citations

70961

41
h-index

56606

83
g-index

108
all docs

108
docs citations

108
times ranked

8193
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of the preparation process for human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics, 2003, 257, 169-180.	2.6	628
2	Desolvation process and surface characterisation of protein nanoparticles. International Journal of Pharmaceutics, 2000, 194, 91-102.	2.6	500
3	Gelatin nanoparticles by two step desolvation a new preparation method, surface modifications and cell uptake. Journal of Microencapsulation, 2000, 17, 187-193.	1.2	340
4	Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1246-1253.	1.3	325
5	Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research, 1997, 14, 325-328.	1.7	321
6	Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics, 2007, 341, 207-214.	2.6	255
7	Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. Journal of Controlled Release, 2007, 118, 54-58.	4.8	247
8	Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials, 2005, 26, 2723-2732.	5.7	209
9	Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. International Journal of Pharmaceutics, 2008, 347, 109-117.	2.6	204
10	Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials, 2005, 26, 5898-5906.	5.7	195
11	Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells. Journal of Drug Targeting, 2004, 12, 461-471.	2.1	193
12	Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials, 2006, 27, 4975-4983.	5.7	190
13	N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochemical Pharmacology, 2010, 79, 413-420.	2.0	171
14	Human serum albuminâ€“polyethylenimine nanoparticles for gene delivery. Journal of Controlled Release, 2003, 92, 199-208.	4.8	164
15	Desolvation process and surface characteristics of HSA-nanoparticles. International Journal of Pharmaceutics, 2000, 196, 197-200.	2.6	141
16	Enhanced drug targeting by attachment of an anti α_v integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 2010, 31, 2388-2398.	5.7	129
17	Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles. Bioconjugate Chemistry, 2008, 19, 2321-2331.	1.8	122
18	Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. Journal of Controlled Release, 2004, 96, 483-495.	4.8	121

#	ARTICLE	IF	CITATIONS
19	Incorporation of biodegradable nanoparticles into human airway epithelium cells – in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 562-570.	1.0	109
20	Albumin nanoparticles with predictable size by desolvation procedure. <i>Journal of Microencapsulation</i> , 2012, 29, 138-146.	1.2	109
21	Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 428-437.	2.0	106
22	Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 70-80.	2.0	99
23	Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. <i>International Journal of Pharmaceutics</i> , 2008, 363, 162-169.	2.6	97
24	Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). <i>International Journal of Pharmaceutics</i> , 2000, 196, 147-149.	2.6	90
25	Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. <i>International Journal of Pharmaceutics</i> , 2000, 211, 67-78.	2.6	83
26	Novel photosensitizer-protein nanoparticles for Photodynamic therapy: Photophysical characterization and in vitro investigations. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2009, 96, 66-74.	1.7	80
27	Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles. <i>Beilstein Journal of Nanotechnology</i> , 2019, 10, 1002-1015.	1.5	79
28	Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. <i>Biomaterials</i> , 2008, 29, 4022-4028.	5.7	74
29	Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. <i>Scientific Reports</i> , 2015, 5, 8202.	1.6	68
30	Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. <i>International Journal of Pharmaceutics</i> , 2007, 337, 346-356.	2.6	66
31	Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 454-463.	1.7	65
32	Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2000, 49, 303-307.	2.0	62
33	Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery. <i>Molecular Pharmaceutics</i> , 2015, 12, 3202-3213.	2.3	60
34	Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties. <i>International Journal of Pharmaceutics</i> , 2010, 393, 254-263.	2.6	56
35	Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 80-87.	2.0	56
36	Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins. <i>Clinical Cancer Research</i> , 2008, 14, 6531-6537.	3.2	48

#	ARTICLE	IF	CITATIONS
37	Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. <i>Beilstein Journal of Nanotechnology</i> , 2019, 10, 1707-1715.	1.5	48
38	Polymeric nanoparticles – Influence of the glass transition temperature on drug release. <i>International Journal of Pharmaceutics</i> , 2017, 517, 338-347.	2.6	47
39	Nanoparticulate flurbiprofen reduces amyloid- β 242 generation in an in vitro blood-brain barrier model. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 51.	3.0	45
40	Downregulation of Plk1 Expression By Receptor-Mediated Uptake of Antisense Oligonucleotide-Loaded Nanoparticles. <i>Neoplasia</i> , 2008, 10, 223-234.	2.3	44
41	Use of Light-Degradable Aliphatic Polycarbonate Nanoparticles As Drug Carrier for Photosensitizer. <i>Biomacromolecules</i> , 2018, 19, 4677-4690.	2.6	42
42	Light-responsive nanoparticles based on new polycarbonate polymers as innovative drug delivery systems for photosensitizers in PDT. <i>International Journal of Pharmaceutics</i> , 2019, 557, 182-191.	2.6	42
43	New Perspective in the Formulation and Characterization of Didodecyldimethylammonium Bromide (DMAB) Stabilized Poly(Lactic-co-Glycolic Acid) (PLGA) Nanoparticles. <i>PLoS ONE</i> , 2015, 10, e0127532.	1.1	42
44	Crystal Engineering of Pharmaceutical Co-crystals: –NMR Crystallography– of Niclosamide Co-crystals. <i>Crystal Growth and Design</i> , 2016, 16, 3087-3100.	1.4	39
45	Characterisation of PEGylated PLGA nanoparticles comparing the nanoparticle bulk to the particle surface using UV/vis spectroscopy, SEC, ¹ H NMR spectroscopy, and X-ray photoelectron spectroscopy. <i>Applied Surface Science</i> , 2015, 347, 378-385.	3.1	35
46	Photosensitizer loaded HSA nanoparticles II: In vitro investigations. <i>International Journal of Pharmaceutics</i> , 2011, 404, 308-316.	2.6	34
47	Reaction of human macrophages on protein corona covered TiO ₂ nanoparticles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 275-282.	1.7	34
48	Doxorubicin-loaded PLGA nanoparticles - a systematic evaluation of preparation techniques and parameters –. <i>Materials Today: Proceedings</i> , 2017, 4, S188-S192.	0.9	33
49	Quantitative bioimaging of platinum group elements in tumor spheroids. <i>Analytica Chimica Acta</i> , 2016, 938, 106-113.	2.6	32
50	Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2010, 101, 340-347.	1.7	31
51	Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. <i>International Journal of Pharmaceutics</i> , 1997, 158, 219-231.	2.6	30
52	Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro. <i>Anti-Cancer Drugs</i> , 2000, 11, 369-376.	0.7	27
53	Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy. , 2002, , 31-36.		26
54	Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. <i>International Journal of Pharmaceutics</i> , 1997, 158, 211-217.	2.6	25

#	ARTICLE	IF	CITATIONS
55	Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells. <i>Nanotechnology</i> , 2011, 22, 245102.	1.3	25
56	A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging. <i>Metallomics</i> , 2014, 6, 77-81.	1.0	25
57	PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. <i>Nanotechnology</i> , 2015, 26, 145103.	1.3	25
58	Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 129, 1-9.	2.0	25
59	The impact of gastrointestinal mucus on nanoparticle penetration – in vitro evaluation of mucus-penetrating nanoparticles for photodynamic therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 133, 28-39.	1.9	25
60	Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part I: Preparation and physicochemical characterization. <i>International Journal of Pharmaceutics</i> , 1996, 137, 67-74.	2.6	24
61	Pharmacological activity of DTPA linked to protein-based drug carrier systems. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 1236-1240.	1.0	23
62	Comparison of cellular effects of starch-coated SPIONs and poly(lactic-co-glycolic acid) matrix nanoparticles on human monocytes. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5221-5236.	3.3	23
63	Light-Responsive Serinol-Based Polycarbonate and Polyester as Degradable Scaffolds. <i>ACS Applied Bio Materials</i> , 2019, 2, 3038-3051.	2.3	23
64	Characterisation of polybutylcyanoarylate nanoparticles: I. Quantification of PCBA polymer and dextrans. <i>International Journal of Pharmaceutics</i> , 1994, 110, 21-27.	2.6	21
65	Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression. <i>Journal of Drug Targeting</i> , 2009, 17, 627-637.	2.1	21
66	Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity. <i>Beilstein Journal of Nanotechnology</i> , 2019, 10, 2062-2072.	1.5	20
67	Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing. <i>International Journal of Pharmaceutics</i> , 2014, 461, 137-144.	2.6	19
68	A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells. <i>International Journal of Pharmaceutics</i> , 2018, 536, 211-221.	2.6	19
69	Light-responsive polymeric nanoparticles based on a novel nitropiperonal based polyester as drug delivery systems for photosensitizers in PDT. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120326.	2.6	19
70	Preparation of Light-Responsive Aliphatic Polycarbonate via Versatile Polycondensation for Controlled Degradation. <i>Macromolecular Chemistry and Physics</i> , 2019, 220, 1800539.	1.1	17
71	Characterization of polybutyleanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis. <i>International Journal of Pharmaceutics</i> , 1996, 128, 189-195.	2.6	15
72	Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice. <i>Anti-Cancer Drugs</i> , 2002, 13, 149-154.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Nanoparticle albumin-bound mTHPC for photodynamic therapy: Preparation and comprehensive characterization of a promising drug delivery system. <i>International Journal of Pharmaceutics</i> , 2020, 582, 119347.	2.6	15
74	Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides – Cellular uptake and enhanced gene delivery. <i>International Journal of Pharmaceutics</i> , 2017, 522, 198-209.	2.6	14
75	pH-Triggered release from surface-modified poly(lactic-co-glycolic acid) nanoparticles. <i>Beilstein Journal of Nanotechnology</i> , 2015, 6, 2504-2512.	1.5	13
76	Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles. <i>International Journal of Pharmaceutics</i> , 2015, 496, 942-952.	2.6	13
77	In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT. <i>International Journal of Pharmaceutics</i> , 2019, 565, 199-208.	2.6	13
78	Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 212-222.	2.0	13
79	Covalent Modification of Human Serum Albumin by the Natural Sesquiterpene Lactone Parthenolide. <i>Molecules</i> , 2015, 20, 6211-6223.	1.7	12
80	Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes. <i>Journal of Chromatography A</i> , 2014, 1346, 97-106.	1.8	9
81	Preparation of Sesquiterpene Lactone-Loaded PLA Nanoparticles and Evaluation of Their Antitypanosomal Activity. <i>Molecules</i> , 2019, 24, 2110.	1.7	9
82	Backbone-Degradable (Co-)Polymers for Light-Triggered Drug Delivery. <i>ACS Applied Polymer Materials</i> , 2021, 3, 3831-3842.	2.0	9
83	Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 150, 108-119.	2.0	8
84	Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier. <i>International Journal of Pharmaceutics</i> , 2020, 589, 119821.	2.6	8
85	Tracking of Magnetite Labeled Nanoparticles in the Rat Brain Using MRI. <i>PLoS ONE</i> , 2014, 9, e92068.	1.1	7
86	Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120146.	2.6	7
87	Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine. <i>Anti-Cancer Drugs</i> , 2000, 11, 479-485.	0.7	6
88	Thermophoretic immunoassay based on autodisplayed Z-domains for the diagnosis of C-reactive protein. <i>Sensors and Actuators B: Chemical</i> , 2018, 258, 1131-1137.	4.0	6
89	Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 134, 77-87.	2.0	6
90	Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester. <i>Biomedical Applications</i> , 1997, 692, 345-350.	1.7	5

#	ARTICLE	IF	CITATIONS
91	Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase. <i>Talanta</i> , 2016, 146, 335-339.	2.9	5
92	Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic- co -glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 43, 430-438.	1.4	5
93	Development of a Lyophilization Process for Long-Term Storage of Albumin-Based Perfluorodecalin-Filled Artificial Oxygen Carriers. <i>Pharmaceutics</i> , 2021, 13, 584.	2.0	5
94	Simple and efficient method for the detection of diethylenetriaminepentaacetic acid. <i>Biomedical Applications</i> , 1999, 736, 299-303.	1.7	4
95	Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems. <i>Journal of Controlled Release</i> , 2010, 148, e117-e118.	4.8	4
96	Rhombic organization of microvilli domains found in a cell model of the human intestine. <i>PLoS ONE</i> , 2018, 13, e0189970.	1.1	3
97	Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 393-417.	1.0	3
98	Backbone vs. side-chain: two light-degradable polyurethanes based on 6-nitropiperonal. <i>Polymer Chemistry</i> , 2021, 12, 4565-4575.	1.9	3
99	Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles. <i>Biomaterials and Biosystems</i> , 2022, 5, 100032.	1.0	3
100	Tuning the protein corona of PLGA nanoparticles: Characterization of trastuzumab adsorption behavior and its cellular interaction with breast cancer cell lines. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103543.	1.4	3
101	Characterisation and cellular uptake of polysorbate 80-coated PLA nanoparticles. <i>Materials Today: Proceedings</i> , 2017, 4, S193-S199.	0.9	2
102	Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease. <i>Journal of Patient Safety</i> , 2022, Publish Ahead of Print, .	0.7	2
103	Nanoparticles for Cell Specific Drug Delivery. <i>Scientia Pharmaceutica</i> , 2010, 78, 546-546.	0.7	0
104	Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid. <i>Journal of Nanoparticle Research</i> , 2015, 17, 1.	0.8	0
105	EB1 modified HSA nanoparticles as non-viral delivery vectors-Influence of peptide concentration on cell uptake. <i>Materials Today: Proceedings</i> , 2017, 4, S174-S179.	0.9	0